文献速递药物相互作用药物不良反应与药物警戒抗栓抗凝管理

达比加群与扑米酮联用后肝酶急性升高一例

Acute elevation of liver function test values following concomitant administration of dabigatran and primidone.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

本文报告一例70岁白人男性从华法林转换为达比加群后,在联用扑米酮的情况下出现肝酶一过性升高超过正常上限5倍,停药并恢复华法林后肝酶恢复基线。因果评估显示可能关联(Naranjo评分3分,RUCAM评分3分),提示扑米酮通过P-糖蛋白诱导可能影响达比加群疗效与安全性。

要点

  • 达比加群与扑米酮联用可能因P-糖蛋白诱导降低达比加群疗效并增加血栓风险。
  • 本病例中联用后出现肝酶一过性升高超过正常上限5倍,停药并恢复华法林后恢复。
  • 使用扑米酮的患者选择抗栓药物时需考虑该潜在相互作用。

核心结论

  • 达比加群与扑米酮联用可能具有临床意义,尤其在扑米酮治疗患者的抗栓药物选择方面。

研究设计与样本

  • 本文为个案报告,对象为一名70岁白人男性,从华法林转换为达比加群后联用扑米酮。

主要发现

  • 达比加群起始约1个月后 routine 门诊随访发现肝酶值大于正常上限5倍。
  • 停用达比加群并恢复华法林后,肝酶值恢复至基线。
  • 因果评估:Naranjo不良反应概率评分为3分,RUCAM评分为3分。

关键数值与推荐

  • 肝酶升高定义为大于正常上限5倍。
  • Naranjo评分3分、RUCAM评分3分提示可能关联。

临床怎么用

  • 对使用扑米酮的患者,选择抗栓药物时应考虑达比加群与扑米酮的潜在相互作用。
  • 联用期间应监测肝酶及血栓风险,出现肝酶升高时考虑停药并替代治疗。

局限性

  • 个案报告,不能确立因果关系。
  • 因果评估评分仅为可能关联,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report a unique case of transiently elevated liver function test (LFT) values associated with concurrent use of dabigatran and primidone, which has not previously been described in the scientific literature. SUMMARY: Management of drug-drug interactions requires a fundamental understanding of pharmacodynamic and pharmacokinetic parameters. Despite the use of available best predictive models, idiosyncratic drug reactions may still occur when a newly approved medication begins to be used in the general population. We report a case of a possible interaction (Naranjo adverse drug reaction probability score of 3, Roussel Uclaf causality assessment method score of 3) between dabigatran and primidone in a 70-year-old Caucasian male resulting in a transient elevation of LFT values. The patient was transitioned from warfarin to dabigatran in the setting of persistently subtherapeutic international normalized ratio values. During a routine outpatient follow-up appointment approximately 1 month after dabigatran initiation, the patient was discovered to have LFT values greater than 5 times the upper limit of normal. Dabigatran was thus discontinued; the patient was returned to warfarin therapy and their LFT values returned to baseline. CONCLUSION: Studies have indicated a potential for reduced dabigatran efficacy with concurrent use of primidone due to P-glycoprotein induction, thereby potentiating the risk for thrombosis. To date, reports of this interaction resulting in hepatic injury are lacking. The present case suggests that this interaction may be clinically significant with regard to selection of antithrombotic medication therapy in patients on primidone therapy.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Caviness LA, Wassell KM, Howard-Thompson A, et al. Acute elevation of liver function test values following concomitant administration of dabigatran and primidone. Am J Health Syst Pharm. 2022. PMID: 35212353. doi:10.1093/ajhp/zxac054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。